SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX:
'NRT'; Nasdaq: 'NVGN') CEO, Dr Graham
Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer
drug being developed by Novogen. Novogen is an Australian-US drug
discovery company focused on the clinical development of drugs
targeting two novel drug targets pertinent to a range of
therapeutic indications.
The interview can be viewed at http://goo.gl/PH737R.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade
on both the Australian Securities Exchange ('NRT') and NASDAQ
('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company,
CanTx Inc., with Yale University.
Novogen has two Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM compounds
target the microfilament component of the cancer cell and when used
in conjunction with standard anti-microtubular drugs, result in
comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites,
prostate cancer, neural cancers (glioblastoma, neuroblastoma in
children) and melanoma are the key clinical indications being
pursued, with the ultimate objective of employing both technologies
as a unified approach to first-line therapy.
Further information is available on our website:
www.novogen.com
For more information please contact:
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4100
|
Media
Enquiries
Cristyn
Humphreys
Chief Operating
Officer
Novogen
Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472
4111
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sky-news-helen-dalley-interviews-dr-graham-kelly-300047982.html
SOURCE Novogen Ltd